Psychedelics landscape - What can we expect?

In partnership with Cybin, we are hosting a panel discussion titled “Psychedelics Landscape – What can we expect?” 

Psychedelics are showing promise in treating mental health conditions, but to ensure their use is not severely limited, legal and other obstacles will need to be navigated. This session will provide insights into the opportunities and challenges surrounding psychedelic medicines, with an expert panel to facilitate a discussion on the political, financial, IP and regulatory considerations on the road to commercial success.

Our expert panel includes:

• Doug Drysdale, CEO, Cybin

• Dr. Christopher Golden, Director - Healthcare & Life Sciences, Peel Hunt 

• Mark Ferguson, Head of Reputation, Crisis, and Client Operations, Pinsent Masons

Who should attend?

This event is aimed at Life Sciences and Healthcare experts.